Robert E. Conway net worth and biography

Robert Conway Biography and Net Worth

Robert Conway has served as a member of Alpine’s Board of Directors since July 2017. Previously, Mr. Conway served as a member of Nivalis Therapeutics’ Board of Directors from April 2015 to July 2017. From 1999 to 2012, Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array BioPharma (NASDAQ:ARRY), a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. (NYSE GLW), including Corporate Vice President and General Manager of Corning Hazleton, a contract research organization. Since 2013, Mr. Conway has served on the board of directors of ARCA BioPharma (NASDAQ:ABIO), a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013, Mr. Conway served on the boards of directors of PRA International (NASDAQ:PRAH), which was a public company for a portion of his tenure there, and Bracket Corp., a private company. Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital. Mr. Conway received a B.S. in accounting from Marquette University in 1976.

What is Robert E. Conway's net worth?: The estimated net worth of Robert E. Conway is at least $3.23 million as of May 12th, 2021. Mr. Conway owns 50,000 shares of Alpine Immune Sciences stock worth more than $3,231,500 as of April 23rd. This net worth estimate does not reflect any other investments that Mr. Conway may own. Learn More about Robert E. Conway's net worth.
How do I contact Robert E. Conway?: The corporate mailing address for Mr. Conway and other Alpine Immune Sciences executives is 188 East Blaine Street Suite 200, Seattle WA, 98102. Alpine Immune Sciences can also be reached via phone at (206) 788-4545 and via email at [email protected]. Learn More on Robert E. Conway's contact information.
Has Robert E. Conway been buying or selling shares of Alpine Immune Sciences?: Robert E. Conway has not been actively trading shares of Alpine Immune Sciences during the past quarter. Most recently, on Tuesday, September 21st, Robert E. Conway bought 10,000 shares of Alpine Immune Sciences stock. The stock was acquired at an average cost of $9.80 per share, with a total value of $98,000.00. Learn More on Robert E. Conway's trading history.
Who are Alpine Immune Sciences' active insiders?: Alpine Immune Sciences' insider roster includes Robert Conway (Director), and Mitchell Gold (CEO). Learn More on Alpine Immune Sciences' active insiders.
Are insiders buying or selling shares of Alpine Immune Sciences?: During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 333,185 shares worth more than $6,451,439.56. The most recent insider tranaction occured on January, 25th when insider James Paul Rickey sold 236 shares worth more than $5,192.00. Insiders at Alpine Immune Sciences own 42.3% of the company. Learn More about insider trades at Alpine Immune Sciences.
Information on this page was last updated on 1/25/2024.

Robert E. Conway Insider Trading History at Alpine Immune Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/21/2021	Buy	10,000	$9.80	$98,000.00
11/19/2020	Buy	10,000	$8.03	$80,300.00
5/9/2017	Buy	5,000	$2.34	$11,700.00	45,000
5/8/2017	Buy	15,000	$2.28	$34,200.00	60,000
5/5/2017	Buy	20,000	$2.30	$46,000.00	40,000
5/4/2017	Buy	10,000	$2.26	$22,600.00	20,000
12/9/2015	Buy	10,000	$8.10	$81,000.00	10,000

Robert E. Conway Buying and Selling Activity at Alpine Immune Sciences

Alpine Immune Sciences Company Overview

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Today's Range

Now: $64.55

$64.50

$64.70

50 Day Range

MA: $41.49

$29.13

$64.58

2 Week Range

Now: $64.55

$6.71

$64.70

Volume

3,104,151 shs

Average Volume

1,937,325 shs

Market Capitalization

$4.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024